Literature DB >> 9639216

Intensification of fetal and maternal surveillance in pregnant women with hypertensive disorders.

M Knuist1, G J Bonsel, H A Zondervan, P E Treffers.   

Abstract

OBJECTIVE: To examine the need to intensify fetal and maternal surveillance in pregnant women with mild pregnancy hypertension.
METHODS: The multi-center cohort study in 2413 healthy nulliparae analyzed differences in hypertension-related adverse events (small-for-gestational age, perinatal mortality, eclampsia, abruptio placentae and HELLP syndrome) according to maximum diastolic blood pressure and proteinuria.
RESULTS: Compared to the reference group (diastolic blood pressure 70-85 mmHg) (n = 1882) the relative risks of adverse fetal and maternal outcome in 34 proteinuric hypertensive women were 8.9 (95% CI 3.3-24.1) and 41.5 (95% CI 9.7-178.4), respectively. In 203 non-proteinuric women with a maximum diastolic blood pressure of > or = 95 mmHg only the relative risk of adverse maternal outcome was increased (11.6, 95% CI 3.1-42.8), but it was not increased in 230 non-proteinuric women with a maximum diastolic of 90 mmHg.
CONCLUSIONS: Intensified surveillance in women with mild pregnancy hypertension is not indicated and should be reserved for groups with increased fetal and maternal risk.

Entities:  

Mesh:

Year:  1998        PMID: 9639216     DOI: 10.1016/s0020-7292(98)00024-1

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  13 in total

1.  Role of bone morphogenic protein-4 in gestational diabetes mellitus-related hypertension.

Authors:  Benshuo Cai; Juan Du
Journal:  Exp Ther Med       Date:  2021-05-13       Impact factor: 2.447

Review 2.  Preeclampsia and diabetes.

Authors:  Tracey L Weissgerber; Lanay M Mudd
Journal:  Curr Diab Rep       Date:  2015-03       Impact factor: 4.810

3.  Haptoglobin phenotype, angiogenic factors, and preeclampsia risk.

Authors:  Tracey L Weissgerber; James M Roberts; Arun Jeyabalan; Robert W Powers; Minjae Lee; Saul A Datwyler; Robin E Gandley
Journal:  Am J Obstet Gynecol       Date:  2012-01-13       Impact factor: 8.661

Review 4.  Flow-mediated dilation: can new approaches provide greater mechanistic insight into vascular dysfunction in preeclampsia and other diseases?

Authors:  Tracey L Weissgerber
Journal:  Curr Hypertens Rep       Date:  2014-11       Impact factor: 5.369

Review 5.  Impaired Flow-Mediated Dilation Before, During, and After Preeclampsia: A Systematic Review and Meta-Analysis.

Authors:  Tracey L Weissgerber; Natasa M Milic; Jelena S Milin-Lazovic; Vesna D Garovic
Journal:  Hypertension       Date:  2015-12-28       Impact factor: 10.190

6.  Is preeclampsia associated with fetal malformation? A review and report of original research.

Authors:  David B Nelson; Lina F Chalak; Donald D McIntire; Kenneth J Leveno
Journal:  J Matern Fetal Neonatal Med       Date:  2014-11-14

7.  Vascular pool of releasable soluble VEGF receptor-1 (sFLT1) in women with previous preeclampsia and uncomplicated pregnancy.

Authors:  Tracey L Weissgerber; Augustine Rajakumar; Ashley C Myerski; Lia R Edmunds; Robert W Powers; James M Roberts; Robin E Gandley; Carl A Hubel
Journal:  J Clin Endocrinol Metab       Date:  2013-12-11       Impact factor: 5.958

8.  Preeclampsia and eclampsia incidence in the eastern anatolia region of Turkey: the effects of high altitude.

Authors:  Yakup Kumtepe; Onur Dündar; Kadir Cetinkaya; Metin Ingeç
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-03-01

Review 9.  Maternal preeclampsia and neonatal outcomes.

Authors:  Carl H Backes; Kara Markham; Pamela Moorehead; Leandro Cordero; Craig A Nankervis; Peter J Giannone
Journal:  J Pregnancy       Date:  2011-04-04

10.  Haptoglobin phenotype, preeclampsia risk and the efficacy of vitamin C and E supplementation to prevent preeclampsia in a racially diverse population.

Authors:  Tracey L Weissgerber; Robin E Gandley; Paula L McGee; Catherine Y Spong; Leslie Myatt; Kenneth J Leveno; John M Thorp; Brian M Mercer; Alan M Peaceman; Susan M Ramin; Marshall W Carpenter; Philip Samuels; Anthony Sciscione; Margaret Harper; Jorge E Tolosa; George Saade; Yoram Sorokin
Journal:  PLoS One       Date:  2013-04-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.